Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_2817_Библиотеки_им_академика_М_И_Перельмана.pdf
Скачиваний:
0
Добавлен:
02.09.2026
Размер:
19 Мб
Скачать
17
the effects of stopping intake were well known: after the rush of energy and euphoric state, and the decreased need to sleep or eat, the users would experience a ‘crash’, dominated by tiredness and depression. Typically, this would lead to further drug intake. The only amphet­amines currently used for medical purposes are dex­amphetamine for narcolepsy and methylphenidate (an amphetamine- related compound) for the treatment of hyperactive children suffering from attention- deficit/ hyperactivity disorder.
Amphetamines can be snorted, taken orally or injected. After heroin, amphetamine is the most abused injected drug in the UK. There is particular concern over the use of methamphetamine, which is stronger than amphetamine and causes an intense and longer­lasting ‘high’. Its chronic use can lead to strong psy­chological dependence and bouts of intense depression after the ‘high’. In 2020 it was estimated that there were
7.4 million dependent amphetamine users worldwide. Dependence on amphetamine/methamphetamine is associated with depression, psychosis, anxiety and car­diovascular disease.
Amphetamine overdose can lead to cardiac arrhyth­mia, paranoid ideation, hyperactivity and hyperthermia. Paranoia may be accompanied by hallucinations, and it is known that amphetamine ingestion can precipitate relapse in schizophrenic patients. The combination of hyperthermia and hyperactivity may lead to an acidotic state, convulsions and death. Intense headache and dys­kinesias may also occur. The management of amphet­amine overdose relies on the use of benzodiazepines and antipsychotics. In the latter category, drugs with an α- adrenergic component are preferred, such as chlor­promazine, in order to counter the increased sympathetic activity. Since amphetamine is a base that is excreted unchanged in the urine, it is possible to acidify urine with ammonium chloride and thus significantly increase the rate of excretion.
At present, there is no satisfactory treatment for addic­tion to amphetamines. A very wide range of treatments have been explored so far, including antidepressant drugs (e.g. mirtazapine), GABA agonists (e.g. baclofen), partial nicotinic cholinergic agonists (varenicline), dif­ferent stimulants (dexamphetamine and methylpheni­date), glutamatergic agents (riluzole), opiate antagonists (naltrexone) and CRF1 antagonists. However, the ben­efits shown are mild and inconsistent across studies. Antipsychotic drugs and short- term benzodiazepines can be used for the management of acute withdrawal symp­toms. Psychosocial interventions that have shown some benefits include cognitive behavioural therapy and con­tingency management.

Methylenedioxymethamphetamine—‘Ecstasy’

One of the most abused recreational drugs is a substituted amphetamine: 3,4- methylenedioxymethamphetamine (MDMA), also called ‘ecstasy’. MDMA is an amphet­amine derivative structurally related to the hallucinogenic
compound mescaline. Since the mid- 1980s, MDMA has become a very popular recreational drug associated with live music venues, especially ‘rave’ parties. Ecstasy tab­lets come in a variety of shapes, sizes and colours. Doses and purity vary widely. A 2012 Dutch study found that the occurrence of significant adverse events after ecstasy use, for example, palpitations, agitation, hyperthermia and seizures, were attributed to the presence of contami­nants such as methylenedioxyamphetamine and meta­chlorophenylpiperazine. The effects of the drug occur after a latent period of 20–60 min and may last for 3–6 h. MDMA users report a state of relaxation and euphoria. The drug appears to increase empathy and to sharpen emotions. It decreases inhibitions and heightens the per­ception of sounds and colours.
The case history illustrates the dangers associated with the use of this drug and the misperception that it is rather mild and innocuous. According to the 2014 United Nations World Drug Report, Australia ranks as the highest per capita consumer of the drug. Most hos­pital admissions and, ultimately, deaths associated with this drug are the result of hyperthermia, which leads to breakdown of skeletal muscle (rhabdomyolysis), and associated multiple organ failure. Furthermore, inges­tion of large volumes of water in an attempt to decrease the effects of hyperthermia and dehydration (due to many hours of dancing, for example) may lead to a typi­cal hyponatraemic syndrome, exacerbated by increased secretion of anti-diuretic hormone. The retention of water leads to dilution of the extracellular medium. The subsequent brain swelling is accompanied by signs of increased intracranial pressure. Death may occur as a result of brain herniation. The case history illustrates a typical toxic ecstasy syndrome, which luckily resolved within 48 h but which may have also ended in the death of the young person involved. Young women are particu­larly sensitive to the toxic effects of ecstasy. In the case history the restoration of a normal Na+ level was prob­ably crucial in saving the life of the patient.
There is increasing concern that the use of ecstasy leads to irreversible brain structural changes. The phar­macodynamic profile of this drug is complex. The acute administration of MDMA leads to increased release of 5- HT in the brain. This effect involves an interaction with the 5- HT reuptake system. MDMA also inhibits MAO activity (with a 10-fold higher potency at MAOA than at MAOB). The drug can also increase dopamine release but its effects may not involve the dopamine transport sys­tem; instead, diffusion into the dopaminergic terminal followed by displacement of dopamine from vesicles. Finally, MDMA can also acutely increase the release of noradrenaline. MDMA binds to a variety of receptors; it shows high affinity for 5- HT2, α2- adrenergic, M1 musca­rinic and H1 histamine receptors, and lower affinity for 5- HT1, β- adrenergic and α1- adrenergic receptors.
Research in monkeys has shown that MDMA has a neurotoxic effect on the 5- HT innervation of the forebrain (see Fig. 17.7). The loss of 5- HT fibres may be partly reversible in some brain structures, but it is question-
ADDICTION
369THE NERVOUS SYSTEM
17
ADDICTION
a
b
Fig. 17.7 Neurotoxicity of MDMA in monkeys exposed semi­acutely to the drug. (a) Dark- field photomicrograph showing 5- hydroxytryptamine (5- HT) fibres in the caudate nucleus (A) in control animals, (B) 2 weeks after a 3- day exposure to MDMA, and (C) 7 years after a 3- day exposure to MDMA. (b) Dark- field photomicrographs showing 5- HT fibres in the hippocampus (A) in control animals, (B) 2 weeks after a 3- day exposure to MDMA, and (C) 7 years after a 3- day exposure to MDMA. H, Hilus; M, the molecular layer; O, stratum oriens; P, stratum pyramidale; R, stratum radiatum. (From Hatzidimitriou et al. (1999). Journal of Neuroscience 19:5096–107.)
able whether full recovery ever occurs. As illustrated in Fig. 17.7, the effects are spectacularly long lasting. Thus, after only three administrations of ecstasy, 7 years before their brain tissue was analysed, the monkeys still showed significantly decreased serotonergic innervation of the striatum and of the hippocampus. Positron emis­sion tomography (PET) studies in chronic ecstasy users confirm that serotonin transmission is altered, raising the possibility that the regular use of ecstasy in humans irreversibly affects serotonergic signalling. Furthermore, it has been shown that long- term use of recreational MDMA leads to discrete changes in brain glucose metab­olism, which can be correlated with specific verbal mem­ory deficits.

Hallucinogens

Drugs that induce mental changes similar to psychotic states are called hallucinogens or ‘psychedelic’ drugs. In 1938 the Swiss chemist Albert Hofmann synthesized the compound lysergic acid diethylamide (LSD) and a few years after its synthesis accidentally ingested some pow­der, subsequently experiencing the ‘mind- expanding’ properties of this compound. The effects (also known as ‘the trip’) were described as a ‘dream- like state’ during which sensory modalities fused. Hallucinations during which sensory modalities are mixed up are called ‘syn-
esthetic’. Interestingly, such hallucinations are sometimes encountered in patients with temporal lobe epilepsy. The sense of time is disrupted but memory is unaffected. Feelings of total detachment and depersonalization may occur. Hallucinogens may affect mood, but the type of effect seen is context- dependent and depends on the mindset of the user. Good ‘trips’ as well as terrifying, bad ‘trips’ can be experienced by the same user. There is increased sympathetic activity, with increased blood pressure and pulse rate, dilated pupils and increased body temperature.
The structure of LSD and other hallucinogens, such as the compounds extracted from the psilocybe mush­room (i.e. psilocybin) or the peyote cactus (i.e. mescalin), are very similar to that of serotonin. It is now well estab­lished that LSD can activate presynaptic 5- HT recep­tors, and thus decrease the activity of raphe serotonergic neurons. This may underlie, at least partly, the effects of the hallucinogen, but the compound has a complex pharmacology, involving several types of 5- HT receptor. LSD is a very potent compound, with 25 µg being suf­ficient to induce hallucinations. Death from LSD over­dose is rare, as the safety range of this compound is wide. When overdose occurs, it manifests as vomiting, respiratory arrest and coma. There is rapid tolerance to the effects of LSD. Hallucinogens may lead to psycho­logical but not physical dependence. Together with can­nabis, ecstasy and amphetamine, LSD is among the most popular drugs with club- goers. Experiencing the effects of psychedelic compounds through ingestion of LSD or ‘magic mushrooms’ (its street name) is a common temp­tation among teenagers in particular, and some of the self- reported effects and consequences are quite disturb­ing. Box 17.5 contains edited fragments of the comments of two people who have eaten ‘magic mushrooms’.
An interesting development in the past 2–3 years has been the new recognition of the potential therapeu­tic value of certain hallucinogens, such as psilocybin, which could have unique therapeutic effects in depres­sion and the management of addictions (e.g. alcohol and tobacco). Like other psychedelic compounds, psilocy­bin exerts agonist effects at 5- HT2A receptors, which are abundantly expressed on the large cortical pyramidal cells. Magnetoencephalography and electroencephalog­raphy show that psilocybin induces an increase in cel­lular firing and, subsequently, desynchronized cortical activity. This enhanced entropy effect leads to an increase in cerebral connectivity patterns, possibly underlying more insights into feelings, motives, beliefs and actions. Notably, the regimen of treatment with these psyche­delic agents is quite different from the usual regimens of drug treatment in these conditions: for example, instead of taking the drug daily, it is administered only on a few occasions over several weeks, and it is used in con­junction with very structured psychotherapy support. Overall, the proponents of this new ‘psychedelic psy­chiatry’, such as the scientists and clinicians at the newly created Centre for Psychedelic Research, at Imperial
370 SYSTEMS OF THE BODY
17
Box
17.5
‘I had a terrible experience yesterday on mushrooms. I had eaten them twice before with no problem This time, when I ate the 8th, I didn’t even finish them all. I felt fine at first. We were going to go to the beach to “people watch”. I got up to go to the bathroom first and all of a sudden I felt extreme anxiety. I have never been so scared in my life. I felt like I was fighting with myself. I started screaming at my boyfriend. Everything I saw was chang­ing and I didn’t know where I was. I was being really mean to him one second and the next second I was apologizing, trying to tell him I didn’t mean it. I could not understand anything that was going on. I had no concept of anything. Even time. I kept asking what time it was. Literally, a min­ute felt like it should have been 2 or 3 hours He tried to put on some soothing music and I made him take it out. I couldn’t even watch commercials with music on televi­sion. Now, 24 hours later, I feel extremely sad and not quite myself. I would appreciate it if you could tell me what happened. How can I get myself feeling normal again?’
experience. I became suicidal and for about 4 days I was totally wasted. Today at the age of 47 I suffer from severe depression and phobias and have had to have electroshock treatment for a breakdown. Could this be related to that bad experience all those years ago, and if so, what help could I get, if there is a cure available?’
Going on ‘trips’
‘I took mushrooms at the age of 20 and had a very bad
College in London, suggest that these agents trigger a profound and long- lasting beneficial neural plasticity.

Solvents

A wide variety of organic compounds that are used as solvents, e.g. in paint, nail varnish remover and glue, as well as cigarette lighter gas or propellant gas used in aerosols, can be abused through inhalation (and so are termed ‘inhalants’). Solvent abuse is commonly called ‘glue- sniffing’ and is a form of addiction that affects mainly adolescents. It is quite common in the UK, and it particularly affects young people in socially deprived areas. These inhalants are rapidly absorbed and lead to a sensation similar to that of being drunk. Irrespective of their structures (i.e. aliphatic or aromatic hydrocarbons, chlorinated hydrocarbons, acetates, ketones, ether or chloroform), these agents initially produce a stimulating effect, which is followed by depression. The molecular targets activated by solvents to induce these effects are not well defined. They include NMDA glutamate recep­tors, nicotinic cholinergic receptors, 5- HT3 receptors and GABAA receptors. The effect is short- lived (usually a few minutes) and repeat doses are required every hour. The user can develop hallucinations and delusions and may slip into a delirious state. Tolerance to solvents can develop very quickly. There is no physical dependence
but there is strong psychological dependence. Chronic exposure to solvents is likely to cause not only neurotox­icity but also hepatotoxicity and renal toxicity. Accidental death can also be caused by suffocation or choking on vomit after intense periods of sniffing that may trig­ger emesis. There is at present no treatment for solvent abuse. Changes in legislation which restricts sales of glues and solvents with high volatile organic compound content are an example of a means of controlling this type of addiction.

Addiction and rehabilitation: general comments

In the treatment of addiction there are three stages at which interventions play an important role: (1) during the active use of the drug, (2) to alleviate the symptoms of withdrawal and (3) to prevent relapse. That addic­tion is a disease of the brain, with complex physical and emotional aspects, is a relatively recent concept in the history of medicine; some scholars have proposed differ­ent theories of addiction and question or reject the brain disease model. For example, an alternative theory is that addiction reflects a distorted deep learning process that can be unlearned. Multiple drug addiction is a common and significant societal problem. Addicts may use, at the same time, varying combinations of alcohol, cocaine, crack, methadone and PCP, and also sniff glue. Each of these drugs, as discussed above, has its own characteris­tics and sometimes their negative effects can be synergis­tic. Cocaine and heroin can lead to tolerance. However, under certain conditions, drugs of abuse such as amphet­amine can lead to the opposite phenomenon, that of sen­sitization, that is, an enhancement of the effects of the drug. Ethanol and opiates lead to physical dependence, whereas cocaine and amphetamine much less so. Cues associated with drug taking play a major role in relapse, either a short time after abuse or after a long period of abstinence. Thus, places, people or the paraphernalia associated with drug abuse can trigger relapse. Stress also appears to act as a triggering factor for relapse in many addictions.
In parallel with the main substance use disorders discussed in this chapter, another trend in society is the emergence of new psychoactive substances, that is, drugs designed to replicate the effects of substances like canna­bis, cocaine and ‘ecstasy’ while remaining legal—hence the alternative names: ‘legal highs’ or ‘designer drugs’. They represent a heterogeneous class of substances, known under various brand names, and include syn­thetic cannabinoids, psychostimulants, compounds with sedative and anti-anxiety effects, and also substances with hallucinogenic properties. These drugs are eas­ily available online and are often adulterated with other compounds. There is increasing evidence that demon­strates their short- term and long- term harm, in particu­lar their strong addictive potential. The Psychoactive Substances Act came into force in the UK in 2016, and
ADDICTION
371THE NERVOUS SYSTEM
17
it is illegal to produce, supply, or import these new sub­stances for human consumption—including for personal use.
The life of an addict can lead to extreme physical and
ADDICTION
moral degradation, as described by the autobiographies or diaries of addicts: ‘I wake to the feeling of something warm dripping down my chin. I lift my hand to feel my face. My four front teeth are gone. I have a hole in my cheek, my nose is broken and my eyes are swollen nearly shut I look at my clothes and my clothes are covered with a colourful mixture of spit, snot, urine, vomit and blood’. There are at present very few efficient ways of treating addiction and, in the future, the answer may lie in an approach based on a better understanding of the com­plex changes induced in the brain by chronic consumption of drugs. Our present understanding of the neurobiol­ogy of addiction indicates that, in the brain of an addict, homeostasis has been replaced by ‘allostasis’, that is, a totally different set point, and efficiently treating addiction will require better characterization of all the neurotrans­mitter and circuit changes involved in this allostatic trans­formation. What is also clear is that the life trajectory of addicts and their substance misuse can be very different: persistent use, declining use, cessation followed by relapse or sustained cessation. There is a need for a better under­standing of the factors that underlie this heterogeneity and the development of reliable biomarkers of relapse, thus leading to improved management of this significant and life- changing brain condition.
Self- assessment case study
Alex recently graduated in engineering and was offered a choice position to work on an oil platform in Scotland. He has decided to celebrate with friends and go out for a drink. He intends to make it a special occasion and drink more than the usual few pints that he drinks almost every night during the week. Whenever he is out with
his friends he has a reputation for ‘drinking everybody under the table’. On the night of the celebration they start the evening with a few whiskies and continue with beer. After several hours of drinking, all of them are seriously drunk. As they leave the pub, they attempt to cross the road and Alex is hit by a car that he did not see. He suf­fers multiple fractures and is taken to the accident and emergency department. The first 24 h in hospital seem to go by in a haze and after the first day Alex starts to feel very unwell, with alternating chills and sweating. During the afternoon of the second day, he becomes aggressive with the nurses and attempts to hit one of them. He also claims that there are bugs in his bed ‘that crawl all over him’. The doctor on duty decides to administer diazepam and keep him under observation over the next 2–3 days.
After studying this chapter, you should be able to
answer the following questions:
1. What is Alex suffering from? The symptoms that Alex is suffering from, taking into account his history of alcohol consumption, correspond to the development of a withdrawal syndrome and a state of ‘delirium tremens’.
2. What are the main risks associated with the condition that he develops in hospital? A patient who develops symptoms of ‘delirium tremens’ must be maintained under observation: there may be onset of seizures, increased confusion and psychotic episodes, and also autonomic instability that will require appropriate management before patient discharge.
3. What long- term treatment can you suggest in Alex’s case? After discharge from hospital, Alex would require an assessment of his habit of consuming regularly large quantities of alcohol. He is likely to have developed alcohol use disorder, which could be managed using a combination of pharmacological and non-pharmacological strategies.
372 SYSTEMS OF THE BODY

Index

Note: Page numbers followed by ‘f’ indicate figures, ‘t’ indicate tables and ‘b’ indicate box.
A
Abducens nerve. See Cranial nerve VI
(abducens nerve) Abnormal ideas, schizophrenia, 319 Abnormal perceptions, schizophrenia,
319 Absence seizures, 280, 282 Absolute refractory period, 42 Acamprosate, alcohol dependence
treatment, 368 Accessory nerve. See Cranial nerve XI
(accessory nerve) Accommodation reflex. See Visual system ACE inhibitors, stroke prevention, 241–242 Acetaminophen (paracetamol), 110 Acetylcholine (ACh), 180
inactivation, 51 as neurotransmitter, 45–46 skeletal muscle contraction, 179–182
Acetylcholinesterase (AChE)
Alzheimer’s disease, 309–310 skeletal muscle contraction, 179–182
ACh. See Acetylcholine (ACh) AChE. See Acetylcholinesterase (AChE) Acoustic neuromas, 168f
case history, 120b, 132–133
Action potentials, 41–42, 42f
absolute refractory period, 42 ion channels, 41–42 relative refractory period, 42 retinal ganglion cells, 139 sequence events, 43t voltage- sensitive K+ channels, 42 voltage- sensitive Na+ channels, 42
Active zones, synaptic transmission, 41–42 Acupuncture analgesia, 99 Acute pain, 93, 93t
nociceptors, 93, 95, 101 non- steroidal anti- inflammatory drugs, 92
opioids, 92 Acyclovir, 269b, 271 Addiction, 356
benzodiazepines, 361
case history, 356b
definition, 356
drug classification, 358b
drug combination, 371
drugs of abuse, 358t
neurobiology, 357–371
physical degradation, 372
rehabilitation, 371–372
schizophrenia, 364–365
See also specific substances Adduction defects, cranial nerve III, 56–57,
57f Aδ fibres, nociceptors, 92 Adoption studies, mood disorders, 339 Advanced glycation products, Alzheimer’s
disease, 308 Affective flattening, schizophrenia, 320 Age of onset, depression, 338–339 Agitated depression, 334 Agoraphobia, 348t Akinesia/bradykinesia, Parkinson’s disease,
205, 205f Alcohol dependence, 366–368
central effects, 367 delirium tremens, 367–368 heritability, 367
Alcohol dependence (Continued)
neurotransmitters, 372.e1 peripheral effects, 367 pregnancy, 367 treatment, 367
Alexia, 154 Alpha rhythm, EEG, 278–280 Alteplase, stroke prevention, 241 Alzheimer’s disease, 302–308
β- amyloid hypothesis, 307 AGEs, 308 biomarkers, 305b calcium homeostasis, 307
α- secretase, 305
protein structure, 305f case history, 296b CT, 298–299 diagnosis, 298–299 differential diagnosis, 314–315 elderly, 296 genetics, 303–304
amyloid precursor protein, 303
APOE gene, 302t, 303–304
presenilins, 303 MRI, 298–299 neuroinflammation, 308
C1q complement receptor, 308
microglia, 308 pathology, 304–307
choline acetyltransferase, 304
neuritic plaques, 304–306, 304f
neurofi brillary tangles, 306–307
neuronal degeneration, 306–307
neurotransmitters, 304 risk factors, 308, 310–311
INDEX
Alzheimer’s disease (Continued)
signs and symptoms, 361 tau pathology, 306–307
hyperphosphorylated tau, 306–307 microtubule bundling, 306–307 tubulin polymerization, 306–307
treatment, 308–312, 308t
amyloid peptide vaccines, 303–304 anti- amyloid strategies, 311–312 antioxidants, 310 anti-tau strategies, 312 cholinesterase inhibitors, 308–310 glutamatergic agents, 310 non- steroidal anti- inflammatory drugs,
310 risk factor reduction, 310–311 secretase inhibition, 311 tau pathology, 306–307
Amacrine cells. See Retina Amantadine, Parkinson’s disease treatment,
213
American Spinal Injury Association (ASIA)
impairment scale, 80, 83t
Amnesia, 299 AMPA receptors, 300–301
antagonists, 308–309 epilepsy, 283–284 hippocampus LTP, 300 ischaemic stroke, 238–241
Amphetamines, 368–369
historical aspects, 368
overdoses, 369 Ampulla, 169, 170f Amygdala, 16–17
connections, 16f
input, 17
learning, 301–302
aversive learning, 301–302 lesions, 14 sagittal plane, 5–6
β- Amyloid hypothesis. See Alzheimer ’s
disease
Amyloid peptide vaccines, Alzheimer’s
disease treatment, 303
Amyloid precursor protein, Alzheimer’s
disease, 306f
Amyotrophic lateral sclerosis (Lou Gehrig’s
disease), 84, 194 case history, 194 genetics, 194b
Analgesia, 78, 91
acupuncture analgesia, 99 arousal, 99 counter- stimulation, 97
non- nociceptive afferents, 97
opioid receptors and ligands, 99 See also specific drugs supraspinal (descending), 97–99, 98f
brain regions, 97–98 direct postsynaptic inhibition, 98 direct presynaptic inhibition, 89 indirect inhibition, 98 locus coeruleus, 98 mechanisms, 99f nucleus raphe magnus, 98, 98f
Analgesia (Continued)
periaqueductal gray, 113f Analgesia flare, 101f Anatomy/organization (of nervous system),
2–7, 6f
function relationship, 30 See also specific organs/structures
Aneurysms, haemorrhagic stroke, 64,
235–236
Angel dust. See Phencyclidine (PCP) Angiography, 229
anterior circulation, 226f clinical examination, 54 left common carotid artery, 232f
posterior circulation, 234f Angiotensin II, hypothalamus, 22, 115 Angular gyrus, 166f
damage effects, 166b Anhydrosis, autonomic nervous system
dysfunction, 29t
Animal models/studies
ecstasy, 369–370
epilepsy. See Epilepsy Anopia, definition, 142t Anoxia, ischaemic stroke, 238 ANS. See Autonomic nervous system (ANS) Anterior cerebral artery (ACA), 226, 226f,
229f
functional anatomy, 231t Anterior choroidal artery, 227 Anterior cord syndrome, 84 Anterior lobes
cerebellum, 194–200
lesions, 200 Anterior spinal arteries, 80 Anterior system branches, cerebral blood
flow, 227, 228f–229f
Anti- amyloid strategies, Alzheimer’s disease
treatment, 311
Anti- cholinergic agents, Parkinson’s disease
treatment, 213
Antibiotics
deafness, 168
meningitis treatment, 267–268
resistance, bacterial meningitis, 267b Anticonvulsant drugs, 287–289, 346
efficacy, 288t
GABA level increase, 288–289, 290f
GABA receptor modulators, 288
meningitis treatment, 267–268
migraine prevention, 114b
neuropathic pain management, 111
See also specific drugs
side effects, 289
teratogenicity, 289
Antidepressant drugs
atypical, 343
classes, 342t
cocaine addiction treatment, 363
delayed effects, 346–347
monoamine reuptake effects, 343t
mood disorder therapy, 346–347
need for new therapeutic targets, 347
See also specific drugs
switching between, 347
Antidopaminergic agents, Huntington’s
disease, 220
Antioxidants, Alzheimer’s disease
treatment, 310
Antipsychotic drugs, 312–313, 327
amphetamine overdoses, 368–369 classification, 327t pharmacodynamics, 328f See also specific drugs side effects, 328–329, 329t
neuroleptic malignant syndrome,
329–330
tardive dyskinesia, 330 Anti-tau strategies, 312 Anti-tau strategies, Alzheimer’s disease
treatment, 312
Anxiety disorders, 348–349, 348t
classification, 348t See also specific disorders treatment, 348–349
benzodiazepines, 349 APOE gene. See Alzheimer’s disease Appearance, mental state examination,
55
Apraxias, 191b
cortical function examination, 61–62 Aqueous humour, 137, 137f Arachnoid mater, 3, 23, 68, 247
spinal cord, 7 Arcuate fasciculus, damage effects, 166b Argyll Robertson syndrome, pupil
asymmetry, 143t Arousal analgesia, 99 Arteriovenous malformations, haemorrhagic
stroke, 236, 236f Ascending pathways
auditory pathways, 163–164 brainstem, 122 defects, somatosensory pathways,
79f Ascending reticular activating system
(ARAS), 93 Aseptic meningitis, 265, 267t Asperger’s syndrome, 332 Aspirin, 110
atherosclerosis, 230
migraine treatment, 113–115 Association auditory cortex (AII), 165 Association nuclei, thalamus, 18–19 Astrocytes, 36–37, 38f
glial fibrillary acidic protein, 36–37
retina, 146–151 Asynchronous firing, motor
unit, 182 Asynergia, 199 Atherosclerosis, 230, 234f, 234b
aspirin, 234b
ATP- dependent Na+ pumps, ischaemic
stroke, 238 Audiometry
balance disorders, 158, 174–175 hearing tests, 167
Auditory and vestibular nerve. See Cranial
nerve VIII (auditory and vestibular
nerve)
374
Auditory brainstem response, hearing
tests, 167
Auditory encoding. See Auditory system Auditory pathways, 163–164, 163f
ascending pathways, 163 bushy cells, 163 cochlear nerve afferents, 163 contralateral lateral lemniscus, 163 dorsal cochlear nucleus, 163 inferior colliculus, 163–164 intensity, 163 lateral lemniscus body, 163–164 location, 163, 163f medial geniculate nucleus, 163 plasticity, 164b stellate cells, 163 superior olivary nucleus, 163–164,
165f trapezoid body, 163 ventral cochlear nucleus, 163
Auditory perception. See Auditory system Auditory receptors. See Auditory system Auditory system, 158–169
auditory encoding, 162 brainstem acoustic reflexes, 164–165 functions, 164b, 167 pathways. See Auditory pathways perception, 162, 165
association auditory cortex, 165 functional imaging, 165 visual system vs., 163, 165
receptors, 160–162
hair cells, 160 inner hair cells, 160 organ of Corti, 160 outer hair cells, 160
See also Ear anatomy sound transduction, 160–162
basilar membrane, 160, 161f
round window, 160–162, 167 Aura, migraine, 112 Auricle (outer ear), 159–160, 159f Autism, 331
treatment, 331–332
Autonomic nervous system (ANS), 20–21,
25–30 dysfunction, 29–30, 29t efferent output, 23–24 enteric system, 25–26 functional organization, 28f neurotransmitters, 27–28 nicotine addiction, 363 parasympathetic division, 26–27 postganglionic neurones, 27 preganglionic neurones, 27 reflex circuitry, 25f sympathetic division, 26 visceral sensations, 26–27
Autoregulation, cerebral blood flow, 225 Aversive learning, amygdala learning,
301–302
Axial plane, brain anatomy, 8f Axons, 34–35
collaterals, 35 injury, 307
B
Babinski sign, 59, 79 Baclofen, trigeminal neuralgia management,
116
Bacterial meningitis, 263–265
antibiotic resistance, 267b Haemophilus influenzae type b, 264 haemorrhagic rash, 263
Listeria monocytogenes, 264 Mycobacterium tuberculosis, 264 Neisseria meningitidis, 263
septicaemia, 263
Staphylococcus aureus, 264 Streptococcus pneumoniae, 263
Balance, 158 Balance disorders, 174–175
causes, 174 diagnosis, 175
audiometry, 175 caloric test, 175 Hallpike’s manoeuvre, 175 posturography, 175
See also specific diseases/disorders treatment, 175
Barbiturates
insomnia therapy, 351
mood disorder therapy, 339 Barthel Index, 237–238 Basal ganglia, 202–204
anatomy, 8f, 14
circuits, 202–204
direct pathway, 203
functional organization, 203f
indirect pathway, 204
lesions, 20–21
movement control, 178
neurotransmitters, 202–204
GABA, 203 nucleus accumbens, 9 opioid receptors, 203 organization, 202–204 striatum, 202 structure, 202–204
Basilar membrane, sound transduction, 160,
161f Basket neurones, cerebellum, 196 Behaviour, mental state examination, 55 Behavioural disorders, schizophrenia, 319–320 Benign paroxysmal positional vertigo
(BPPV), 174–175 Benserazide, L- DOPA combination, 210–211 Benzodiazepine receptors, insomnia therapy,
353b Benzodiazepine(s)
abuse potential, 350 amphetamine overdoses, 368–369 anxiety disorder treatment, 349–351 complications in elderly, 351t epilepsy treatment, 287–291 insomnia therapy, 351 mechanisms of action, 221.e1 pharmacokinetics, 287–288, 350–351, 351t See also specific drugs in sleep disturbances, 353
Berry aneurysms, haemorrhagic stroke,
235–236, 236f
β- blockers
cocaine addiction treatment, 363
migraine prevention, 114b Bilateral signs, brainstem lesions, 131 Biofeedback, pain perception, 100, 349 Bipolar cells. See Retina Bipolar disorder, 335–339, 345–346
genetics, 345 imaging, 345 lithium, 345
neuronal atrophy, 345 Bipolar neurons, 35, 36f Bladder dysfunction, autonomic nervous
system dysfunction, 3 Blind spot, 139 Blindness
river blindness, 136 Blindsight, 154 Blink reflexes, brainstem, 130 Blood flow rate, 234b Blood tests, dementia, 283, 298–299 Blood–brain barrier, 209, 256, 261–263, 262f
P- glycoproteins, 261
transporters, 261 Bone cancer pain, 106b Botulinum toxin, 116, 180 Bowel dysfunction, autonomic nervous
system dysfunction, 29t
BPPV (benign paroxysmal positional
vertigo), 174–175 Brachiocephalic arteries, 227–228 Bradykinesia/akinesia, Parkinson’s disease,
205, 205f Brain anatomy, 3–7
blood flow. See Cerebral blood flow gyri, 4–5, 5f internal, 7–12
axial plane, 8f coronal sections, 8–11, 9f–10f horizontal sections, 11–12, 12f midsagittal section, 9f sagittal sections, 6f, 7–8
medulla, 6
closed, 6 corticospinal tract, 6 inferior olivary nuclei, 6 open, 6 pyramids, 6
pons, 4–5
trigeminal nerve, 6
See also specific structures sulci, 4–5, 5f supraspinal (descending) analgesia, 97–99 surface features, 4–5, 5f
central sulcus, 4 lateral fissure of Sylvius, 4 longitudinal fissure, 4, 7–8, 9f
parieto- occipital sulcus, 4 symmetry, 14 ventricular system, 2–3, 7, 8f
CSF, 7
Brain contusions/lacerations, head injury,
249–250
INDEX
375
INDEX
Brain hemisphere, left
fine movements, 15 language, 15–16
Brain hemisphere, right
lesion studies, 22 spatial movements, 15
Brain hemisphere(s), specialization, 14–16,
14f, 16f language centres, 14 writing, 14
Brain injury
See also specific types of injury swelling, 250 tumours, 247f
Brainstem, 2, 6, 120
anatomy, 3–12, 121–122, 122f
ascending tracts, 122 blood supply, 126, 129f, 224 cranial nerve association, 120 dorsal view, 122–123 mediolateral plane, 122 MRI, 121–122 reticular formation. See Reticular
formation (RF)
superior view, 123f ventrolateral system, 76 Wiegert–Pow stained sections, 121f
functions, 122t
accommodation reflex, 130 acoustic reflexes. See Auditory system blink reflexes, 130 conduit functions, 120 cranial nerve- related functions, 119 Doll’s eye (vestibulo- ocular)
reflex, 130
gag reflex, 130 heart rate control, 128f, 128b integrative functions, 120 jaw jerk reflex, 130 pupillary light reflex. See below reflexes, 125t, 126
lesions, 130–132
bilateral signs, 131 compression injuries, 131–132 unilateral lateral, 130, 131t unilateral medial, 130, 131t
pupillary light reflex, 127–130, 129t, 141
Edinger–Westphal nucleus, 127–129 Horner’s syndrome, 127–129, 128f
See also specific reflexes
Brainstem death, 129b Broca’s area, 14
damage, 166b
cortical function examination, 167–168 speech understanding, 166b
Brodmann’s area, discriminative touch
system, 74–75
Buprenorphine, 108
opiate addiction therapy, 361–362
Bupropion, 343, 346
smoking cessation, 366
Bushy cells, auditory pathways, 163 Buspirone, 351 Butyrylcholinesterase, 51
C
C- fibres, nociceptors, 92 C1q complement receptor, Alzheimer’s
disease, 308 CA1 outputs, hippocampus LTP, 136 CA3 neurons, hippocampus LTP, 300 CAG repeats, huntingtin, 219–220 Calcarine sulcus, 141f Calcium channels, epilepsy, 284 Calcium homeostasis, Alzheimer’s disease
β- amyloid hypothesis, 307 Calcium- channel blockers (CCBs)
migraine prevention, 115 Callosomarginal artery, 227 Callosotomy, epilepsy, 291 Caloric test, balance disorders, 175 Canal of Schlemm, 137, 137f Cancer pain, 106b
WHO analgesic ladder, 106t, 106b Cannabinoid receptors, 364b Cannabis (marijuana), 363–365, 364b
cannabinoid receptors, 364
depolarization- induced suppression of
inhibition, 364 mechanism of action, 364 modulatory effects, 364, 365f
Carbamazepine
depression therapy, 346 efficacy, 288t epilepsy treatment, 288 trigeminal neuralgia management, 116
Carbidopa, L- DOPA combination, 211–212 Cataracts, 137 Caudate nucleus, sagittal plane, 9–10 Caudate nuclei
horizontal sections, 11–12 movement, 202
Cell injury mechanisms, ischaemic stroke.
See Ischaemic stroke
Cell transplantation
Parkinson’s disease treatment, 215–216,
215f, 215t spinal cord injury management, 85–86
Cellular neuroscience, 33–52 Central cord syndrome, 84 Central nervous system (CNS), 2–3
anatomy, 3 pain perception. See Pain See also specific components
Central neurotransmitters, 45–46 Central pathways, vestibular system,
173–174, 174f
Central sulcus, 4
brain anatomy, 5f
Centre- surround fields, visual contrast
detection, 149, 149f
Cephalosporins, resistance, 267b Cerebellum, 194–200
anatomy, 6f, 194–195
anterior lobe, 195 blood supply, 226–229 cerebrocerebellum. See below deep cerebellar nuclei. See below
Cerebellum (Continued)
paramedian region, 197 posterior lobe, 195
cerebrocerebellum, 197, 198f
motor skills, 197–198 cuneocerebellar pathway, 195t deep cerebellar nuclei, 197
dentate nucleus, 197 diseases/disorders, 198–200
anterior lobe lesions, 200
causes, 199t
genetic causes, 198–199
posterior lobe lesions, 200
trauma, 199
vermis lesions, 200 flocculonodular lobe, 197 functional organization, 197–198
midline nodulus, 197
paired flocculus, 197
vermis, 197
vestibulocerebellum, 197 input pathways, 195t long- term depression, 301
metabotropic glutamate
receptors, 301
procedural (motor) learning, 301 microcircuitry, 195–196, 196f
basket neurones, 196
climbing fibres, 195
Golgi cells, 196
granule cells, 196
mossy fibres, 195
Purkinje cells, 196
stellate neurones, 196 movement control, 178–179, 198, 198f
feedback control, 198, 199f
feedforward control, 198, 199f olivocerebellar pathway, 195t pontocerebellar pathway, 195t spinocerebellar pathway, 195, 195t
locomotor coordination, 197
vestibulocerebellar pathway input, 197 trigeminocerebellar pathway, 195t vestibulocerebellar pathway, 195, 195t,
198f
spinocerebellar tract input, 197
Cerebral abscesses, 256–257, 269–270, 269f Cerebral blood flow
cerebral perfusion pressure, 225 control, 225–226
autoregulation, 225
blood flow rate, 225
hypercarbia, 225
hypocarbia, 225
hypoxia, 225
vasodilating agents, 225 See also specific vessels supply, 226–229
anterior system branches, 226–227, 228f,
231f
posterior system branches, 226–228,
228f
venous system, 228–229, 230f
functional anatomy, 229, 231t
376
Cerebral cortex
anatomy, 12 blood supply, 226–229 chandelier cells, epilepsy, 285, 287f clinical examination. See Clinical
examination discriminative touch system, 74–76 EEG, 278 functional anatomy, 14f pain perception, 95b primary areas, 12f regions of association, 11, 11f
Cerebrocerebellum. See Cerebellum Cerebrospinal fluid (CSF)
blockage, spinal cord syndromes, 137 circulation, 259–263 composition, 259, 259t examination, 64–65 flow, 260f maximum lumbar pressure, 65 normal volume, 65 production, 259–263, 259f
choroid epithelial cells, 259–260
sampling, meningitis. See Meningitis
Cerebrum, sagittal plane, 7–8 Chemical synapses, 44 Chemoreceptors, 22–23, 22t Childhood absence epilepsy (CAE), 276t Chloramphenicol, resistance, 267b Chlorpromazine, 328b
schizophrenia therapy, 327
Choline acetyltransferase (CAT),
Alzheimer’s disease, 304
Cholinergic cells, reticular formation, 126 Cholinergic system, depression, 341 Cholinesterase inhibitors, Alzheimer’s
disease treatment, 308–309
Chorea, Huntington’s disease, 220 Choroid, 137, 137f
epithelial cells, CSF production, 259–260
Chronic insomnia, 352 Chronic pain, 92t Chronic traumatic encephalopathy, 250–251 Ciliary body, 137, 137f Ciliary process, 137 Cingulate cortex, functions, 17 Cingulate gyri, 4–5, 5f, 16
limbic system, 16
Cingulate sulcus, 4–5, 5f Circadian rhythm, hypothalamus, 21 Circle of Willis, 226–227, 226f Circulatory input, hypothalamus, 20 Citalopram, 343 Claustrum nucleus, sagittal plane, 9–10 Climbing fibres, cerebellum, 314 Clinical examination, 54
coordination, 60 cortical function, 61–62
apraxias, 61 Broca’s area damage, 61–62 constructional apraxia, 61 Glasgow Coma Scale, 62 graphesthesia, 61 higher mental skills, 61
Clinical examination (Continued)
parietal lobe lesions, 61 spatial awareness, 61 speech abnormalities, 61–62 stereognosis, 61 Wisconsin card- sorting test, 61
working memory, 61 cranial nerves, 56–58 CSF examination, 64–65 electrical activity, 64 gait, 60
Parkinson’s disease, 60
postural stability, 60
Romberg test, 60 mental state, 55–56
appearance, 55
behaviour, 55
confusion, 55
impaired concentration, 56
mood, 55
obsessional ruminations, 56
perceptual abnormalities, 56
speech, 55
suicidal ideation, 55 motor function, 58–60
muscle power, 59, 59t
muscle tone, 59
visual inspection, 59 neuroimaging, 62–64 patient history, 54 physical examination, 54 reflexes, 59–60
Babinski sign, 59
deep tendon reflexes, 59
hyperreflexia, 59
superficial reflexes, 59–60
See also specific cranial nerves See also specific methods
sensory examination, 60–61
lesion site identification, 61
nociception, 60–61 temporal data, 54
Clobazam
efficacy, 288t epilepsy treatment, 288
Clomipramine, depression and anxiety, 354.
e1 Clonazepam, epilepsy treatment, 288 Clonic seizures, 275 Clonidine, opiate addiction therapy, 361 Clozapine, schizophrenia therapy, 361 CNS. See Central nervous system (CNS) Cocaine addiction, 356, 362–363
tolerance, 363 treatment, 363
withdrawal, 362 Cochlea, 159f, 160, 161f Cochlear implants, 169 Cochlear nerve, 159f
afferents, 163
damage, 165–167
conduction deafness, 166–167 nerve deafness, 166–167
Codeine, 108
Cognitive behavioural therapy (CBT)
depression, 345 pain perception, 100
Cognitive function
dementia, 296
prefrontal cortex, 326b Cognitive therapy, schizophrenia, 330 Colour blindness, 139b Colour vision
cones, 146–147
retinal ganglion cells, 151, 151f Complete spinal cord transection, 84 Complex cells, visual cortex, 152–153 Complex partial seizures, 282 Compression
brainstem, 131–132
spinal cord syndromes, 83 Computed tomography (CT)
clinical examination, 62
dementia, 298–299, 298f
epilepsy diagnosis, 281
Huntington’s disease, 218–219
MRI vs., 62–63
schizophrenia, 322
spinal cord, 81–82 Concentration, impaired, mental state
examination, 56 Concussion, 250–251 Conduction aphasia, lesions, 166b Conduction deafness, 166–167 Conduit functions, brainstem, 120 Cone cells, 146–147
colour vision, 146–147 opsins, 148 spectral sensitivity, 147f structure, 148f
Confusion
dementia vs., 297t mental state examination, 55 Parkinson’s disease, 206
Congenital insensitivity to pain with
anhydrosis (CIPA), 91 Conjunctiva, 136–137, 137f Constructional apraxia, cortical function
examination, 61 Contralateral lateral lemniscus, auditory
pathways, 163 Contralateral tracts, visual pathways, 140 Contrast detection. See Retina Contre- coup’ brain damage, 249–250 Cornea, 137f Coronal sections, brain anatomy, 8–11, 9f–11f Coronary heart disease, nicotine addiction,
366 Corpus callosum, 5f
horizontal sections, 4–5 Corticobulbar tract, motor systems, 188 Corticolimbic circuits, schizophrenia,
322–324, 324f
Corticospinal tract (CST)
medulla, 6
motor systems, 188 Corticotrophin- releasing factor (CRF),
depression, 341
INDEX
377
INDEX
Counter- stimulation analgesia. See
Analgesia
Coup’ brain damage, 249–250 Crack. See Cocaine addiction Cranial motor functions, reticular formation,
126
Cranial nerve I (olfactory nerve), 124t
examination, 56
Cranial nerve II (optic nerve), 124t
clinical examination, 56
Cranial nerve III (oculomotor nerve), 124t
clinical examination, 56–57
adduction defects, 56–57, 57f
eye movement, 144
Cranial nerve IV (trochlear), 124t
clinical examination, 56–57
Horner’s syndrome, 56–57, 57f pupil dilation, 56–57
Cranial nerve IX (glossopharyngeal nerve),
124t
clinical examination, 58
Cranial nerve V (trigeminal nerve), 124t
clinical examination, 57
touch/pin- prick testing, 57
Cranial nerve VI (abducens nerve), 124t
clinical examination, 56–57
Cranial nerve VII (facial nerve), 124t
clinical examination, 57–58, 58f
Cranial nerve VIII (auditory and vestibular
nerve), 124t
clinical examination, 58
nystagmus, 58 Rinne’s test, 58 vertigo, 58 Weber’s test, 58
Cranial nerve X (vagus nerve), 124t
clinical examination, 58 stimulation, depression therapy, 345
Cranial nerve XI (accessory nerve), 124t
clinical examination, 58
Cranial nerve XII (hypoglossal nerve), 124t
clinical examination, 58
Cranial nerve(s), 24, 120, 124t
anatomy, 120 brainstem association, 120–123 classification, 120t clinical examination, 56–58 functions, 120 spinal nerves vs., 123b
CREB (cyclic AMP response- element
binding protein), addiction, 359
Creutzfeldt–Jakob disease (CJD), 257, 314
prion protein, 314 Crista, vestibular system, 170f Crossed extensor reflexes, polysynaptic
reflexes, 186, 186f
CT. See Computed tomography (CT) Cuneocerebellar pathway, cerebellum,
195t Curare, 180–181 Cutaneous nociceptors, 93 Cutaneous referred areas, pain, 96f Cyclic AMP response- element- binding
protein (CREB), addiction, 359
Cyclo- oxygenase (COX) inhibition,
nonsteroidal anti- inflammatory
drugs, 110 Cytoskeleton, neurones, 35 Cytotoxic brain swelling, head injury, 244b
D
DAI (diffuse axonal injury), 250 Daytime sedation, benzodiazepines, 353 DCN (dorsal cochlear nucleus), 163 Deafness, 158
causes, 167–168
gradual deterioration, 168 hereditary disease, 168
tumours, 168f conduction, 166–167 infections, 167–168
perinatal, 168
prenatal, 167–168 nerve, 166–167 ototoxic agents, 168 treatment, 168–169
cochlear implants, 169
hearing aids, 169
tympanostomy tubes (grommets), 169
Decerebrate rigidity, upper motor neurones,
192b Declarative learning, 299 Decorticate rigidity, upper motor neurones,
192b Decreased pain threshold, peripheral
sensitization, 101 Deep brain stimulation (DBS), depression
therapy, 345 Deep cerebellar nuclei. See Cerebellum Deep cerebral veins, 228–229 Deep tendon reflexes, 183t
examination, 59 Déjerine’s syndrome, 131 Delirium tremens, 368b Delta (δ) opioid receptors, 107, 108t Delta rhythm, EEG, 278–280 Delusions, solvent abuse, 371 Dementia, 296
case history, 296b
causes, 296–299, 297t
confusion vs., 297t
definition, 296
depression, 314–315
diagnosis, 296–299
blood tests, 298–299 cognitive function, 296 CT, 269f, 298–299 Mini Mental State Examination,
297–298, 298t MRI, 298–299 psychological testing, 297
management, 314–315 neurobiology, 322–327
Parkinson’s disease, 216–218 Dementia with Lewy bodies, 312–313 Demyelinating disease, spinal cord injury, 80t
Demyelinating diseases, 39b Dendrites, neurones, 34 Dentate gyrus, hippocampus LTP, 285 Dentate nucleus, cerebellum, 5–6 Depolarization- induced suppression of
inhibition, cannabis, 364
Depression
age of onset, 338–339 agitated, 334 brain structures, 339–340 case history, 335b, 348 DSM- IV, 335t epidemiology, 335–339 neurobiology, 339–341 neurochemistry, 340–341 prefrontal cortex hypometabolism, 339f psychotherapy, 345 ratings, 335–338
Hamilton Rating Scale, 336b–338b resistance to, 346–347 retarded, 334 See also Antidepressant drugs specific
drugs sleep disorders, 351 somatic symptoms, 334 suicide risk, 347 treatment, 349–351
electroconvulsive therapy, 344–345 pharmacological management, 341–343
Dermatomes, 24–25, 26f
functions, 27t
Descending somatosensory pathways,
78–79, 79f, 79t
Desynchronicity, EEG, 278–280 Detached retina, 146 Diagnostic and Statistical Manual of Mental
Disorders (DSM- IV) depression, 335t mood disorders, 335t schizophrenia, 320–321
Diamorphine (heroin), 108, 361 Diazepam, 350–351
pharmacokinetics, 350t status epilepticus, 292
Diencephalon
anatomy, 18 blood supply, 226 epithalamus, 18
Dietary treatment, epilepsy, 291–292 Diffuse axonal injury (DAI), 250 Diffuse nuclei, thalamus, 18–19 Dihydroergotamine, migraine treatment, 113 Direct pathway, basal ganglia, 203 Direct postsynaptic inhibition, supraspinal
(descending) analgesia, 98
Direct presynaptic inhibition, supraspinal
(descending) analgesia, 98
Discriminative touch system
somatosensory pathways, 79 spinal cord. See Spinal cord
Disorientation, Parkinson’s disease, 206 Disulfiram, alcohol dependence treatment,
367–368
Diuretics, stroke prevention, 241–242
378